PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26595724-12	2016	In the base-case analysis, among patients receiving 8 or 12 weeks of sofosbuvir-ledipasvir treatment, treating all fibrosis stages compared with treating stages F3 and F4 adds 0.73 QALYs and $28,899, for an ICER of $39,475 per QALY gained.	Sofosbuvir	69-79	cAMP responsive element modulator	Homo sapiens	207-211	
27276081-8	2016	RESULTS: Sofosbuvir/ledipasvir was cost-effective in treatment-experienced patients with an ICER of US$21,612.	Sofosbuvir	9-19	cAMP responsive element modulator	Homo sapiens	92-96	
26595724-18	2016	A 46% reduction in cost of sofosbuvir-ledipasvir therapy decreases the ICER for treating at all fibrosis stages by 48%.	Sofosbuvir	27-37	cAMP responsive element modulator	Homo sapiens	71-75	
25847572-11	2015	In genotype 3, sofosbuvir had a weighted ICER of $18 761/QALY.	Sofosbuvir	15-25	cAMP responsive element modulator	Homo sapiens	41-45	
25820703-11	2015	RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients.	Sofosbuvir	43-53	cAMP responsive element modulator	Homo sapiens	35-39	
25820703-12	2015	RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively.	Sofosbuvir	45-55	cAMP responsive element modulator	Homo sapiens	37-41	
25820703-12	2015	RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively.	Sofosbuvir	192-202	cAMP responsive element modulator	Homo sapiens	37-41	
30791790-4	2018	For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy.	Sofosbuvir	69-79	cAMP responsive element modulator	Homo sapiens	38-42	
30791790-4	2018	For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy.	Sofosbuvir	81-84	cAMP responsive element modulator	Homo sapiens	38-42	
25775312-11	2015	RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY.	Sofosbuvir	31-41	cAMP responsive element modulator	Homo sapiens	101-105